3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Common Variable Immunodeficiency
1
Agammaglobulinemia
1
Interventions
Cyclophosphamide
62
Rituximab
47
fludarabine
35
fludarabine phosphate
27
obinutuzumab
17
Mycophenolic Acid
16
ibrutinib
15
Whole-Body Irradiation
15
Lenalidomide
15
Specimen Handling
14
Prednisone
14
Etoposide
14
venetoclax
13
pirtobrutinib
13
Doxorubicin
13
pembrolizumab
12
Tacrolimus
12
Magnetic Resonance Spectroscopy
11
Granulocyte Colony-Stimulating Factor
11
Filgrastim
11
Biopsy
11
Vincristine
10
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
X-Rays
9
Bendamustine Hydrochloride
9
polatuzumab vedotin
8
glofitamab
8
acalabrutinib
8
Immunotherapy, Adoptive
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Non-Hodgkin
×
Hizentra
×
1 year
×
Clear all
NCT07582432
2026-05-12
SIGMA
Grifols Biologicals, LLC
Phase 3
Recruiting
49 enrolled